http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
우상명,주정남,이우진,박상재,한성식,김태현,고영환,김현범,홍은경 대한의학회 2013 Journal of Korean medical science Vol.28 No.2
Several studies have reported that ABO blood group, hepatitis B virus (HBV) and hepatitis C virus (HCV) infection contribute to the development of pancreatic cancer. The aim of this study was to evaluate the association between these factors and pancreatic cancer in the Korean population. We retrospectively recruited 753 patients with pancreatic cancer and 3,012 healthy controls, matched 4 to 1 with cancer patients for age and sex, between 2001 and 2011, at the National Cancer Center, Korea. A multivariate logistic regression analysis was employed to estimate adjusted odds ratios (AORs). The AOR for pancreatic cancer in subjects with non-O blood types (A, AB, and B), compared to blood type O, was 1.29 (95% CI, 1.05-1.58; P = 0.01). Seropositivity for hepatitis B virus surface antigen was not significantly related to pancreatic cancer, either in univariate (odds ratio 1.03;95% CI, 0.69-1.53; P = 0.91) or multivariate analysis (AOR, 1.02; 95% CI, 0.67-1.56;P = 0.93). The AOR for pancreatic cancer in subjects displaying seropositivity for anti-HCV was 2.30 (95% CI, 1.30-4.08; P < 0.01). Our results suggest that the non-O blood types and anti-HCV seropositivity, but not HBV infection, may increase the risk of developing pancreatic cancer in Korea, where HBV is endemic.
우상명 ( Sang Myung Woo ) 대한소화기학회 2017 대한소화기학회지 Vol.69 No.3
The term of biliary tract cancer (BTC) refers to all tumors that arise from the biliary tract or the biliary drainage system, including the intra- and extra-hepatic bile ducts as well as the gallbladder. BTCs are aggressive tumors with limited treatment options and poor overall survival. Currently, surgery remains to be the only potentially curative treatment, and most patients develop recurrence. For advanced tumors, only limited effective treatment modalities exist today. Gemcitabine plus cisplatin is considered as a standard option for advanced biliary cancer. A randomized phase III trial (ABC-02 trial) showed superiority of gemcitabine plus cisplatin over gemcitabine alone. In that study, they showed that after a median follow-up of 8.2 months, the median overall survival was 8.1 months in the gemcitabine-only group and 11.7 months in the gemcitabine plus cisplatin group (p<0.001). However, while this is a definite advancement, a 3-month survival extension among patients with BTC is modest at best. Moreover, this regimen has not been compared head-to-head with other gemcitabine based combinations. Gemcitabine monotherapy, 5-fluorouracil plus leucovorin, and single- agent capecitabine are all reasonable options for patients with a borderline performance status. Recent advancements have provided new insight into the genomic landscape of BTCs, and thus, it remains unclear whether combined treatment with molecular targeted agents or other cytotoxic chemotherapeutic agents may also be effective against advanced BTC. (Korean J Gastroenterol 2017;69:172-176)
담도, 췌장 : 췌장 낭종의 감별진단을 위한 세침흡인술
우상명 ( Sang Myung Woo ),민병훈 ( Byung Hoo Min ),최기돈 ( Kee Don Choi ),강정묵 ( Jung Mook Kang ),김세중 ( Se Joong Kim ),황진혁 ( Jin Hyeok Hwang ),정지봉 ( Ji Bong Jeong ),김용태 ( Yong Tae Kim ),윤용범 ( Yong Bum Yoon ),박 대한소화기학회 2002 대한소화기학회지 Vol.40 No.6
Background/Aims: Pancreatic cystic neoplasms (PCNs) comprise a pathologically heterogeneous group with many shared clinical features. Diagnostic methods to distinguish mucinous cystic tumors (MCTs) from other cysts are limited. We assessed the reliability of the cystic fluid analysis measuring CEA, CA19-9, and amylase, cytological analysis and mucin staining in the differential diagnosis of PCNs. Methods: Cystic fluid was obtained from 78 pancreatic cysts using fine needle aspiration. These lesions include 17 MCTs, 13 serous cystadenomas (SCAs), 5 solid pseudopapillary tumors (SPTs), 8 intraductal papillary mucinous tumors (IPMTs), 6 ductal carcinomas with cystic degeneration, and 29 pseudocysts. Results: Epithelial cells were observed in 27 (81%) of 33 PCNs, and cytological diagnosis was possible in 5 (31%) of 16 MCTs. Mucicarmine staining was positive only in 5 MCTs, one cystic adenocarcinoma and one IPMT but not in any cases of other cysts. CEA levels of cystic fluid more than 466 ng/mL had 86.7% sensitivity and 97.6% specificity for detecting MCTs. On the other hand, amylase levels over 479 U/dL had 72.7% sensitivity and 89.5% specificity for detecting pseudocysts. Conclusions: Cystic fluid analysis measuring cytology, mucin staining, CEA and amylase levels is useful in the differential diagnosis of pancreatic cysts. (Korean J Gastroenterol 2002;40:394-401)